96 related articles for article (PubMed ID: 28818988)
1. Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma.
Veldhuijzen van Zanten SEM; Sewing ACP; van Lingen A; Hoekstra OS; Wesseling P; Meel MH; van Vuurden DG; Kaspers GJL; Hulleman E; Bugiani M
J Nucl Med; 2018 Apr; 59(4):612-615. PubMed ID: 28818988
[TBL] [Abstract][Full Text] [Related]
2. Molecular Drug Imaging:
Jansen MH; Veldhuijzen van Zanten SEM; van Vuurden DG; Huisman MC; Vugts DJ; Hoekstra OS; van Dongen GA; Kaspers GL
J Nucl Med; 2017 May; 58(5):711-716. PubMed ID: 27765855
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.
Jansen MH; Lagerweij T; Sewing AC; Vugts DJ; van Vuurden DG; Molthoff CF; Caretti V; Veringa SJ; Petersen N; Carcaboso AM; Noske DP; Vandertop WP; Wesseling P; van Dongen GA; Kaspers GJ; Hulleman E
Mol Cancer Ther; 2016 Sep; 15(9):2166-74. PubMed ID: 27325687
[TBL] [Abstract][Full Text] [Related]
4. A Distinct Advantage to Intraarterial Delivery of
Lesniak WG; Chu C; Jablonska A; Du Y; Pomper MG; Walczak P; Janowski M
J Nucl Med; 2019 May; 60(5):617-622. PubMed ID: 30315146
[TBL] [Abstract][Full Text] [Related]
5. Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.
van Asselt SJ; Oosting SF; Brouwers AH; Bongaerts AH; de Jong JR; Lub-de Hooge MN; Oude Munnink TH; Fiebrich HB; Sluiter WJ; Links TP; Walenkamp AM; de Vries EG
J Nucl Med; 2014 Jul; 55(7):1087-92. PubMed ID: 24790218
[TBL] [Abstract][Full Text] [Related]
6. 89Zr-bevacizumab PET imaging in primary breast cancer.
Gaykema SB; Brouwers AH; Lub-de Hooge MN; Pleijhuis RG; Timmer-Bosscha H; Pot L; van Dam GM; van der Meulen SB; de Jong JR; Bart J; de Vries J; Jansen L; de Vries EG; Schröder CP
J Nucl Med; 2013 Jul; 54(7):1014-8. PubMed ID: 23651946
[TBL] [Abstract][Full Text] [Related]
7. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.
Oosting SF; van Asselt SJ; Brouwers AH; Bongaerts AH; Steinberg JD; de Jong JR; Lub-de Hooge MN; van der Horst-Schrivers AN; Walenkamp AM; Hoving EW; Sluiter WJ; Zonnenberg BA; de Vries EG; Links TP
J Nucl Med; 2016 Aug; 57(8):1244-50. PubMed ID: 27173161
[TBL] [Abstract][Full Text] [Related]
8. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
9. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
[TBL] [Abstract][Full Text] [Related]
10. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
Oosting SF; Brouwers AH; van Es SC; Nagengast WB; Oude Munnink TH; Lub-de Hooge MN; Hollema H; de Jong JR; de Jong IJ; de Haas S; Scherer SJ; Sluiter WJ; Dierckx RA; Bongaerts AH; Gietema JA; de Vries EG
J Nucl Med; 2015 Jan; 56(1):63-9. PubMed ID: 25476536
[TBL] [Abstract][Full Text] [Related]
11. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
[TBL] [Abstract][Full Text] [Related]
12.
van Es SC; Brouwers AH; Mahesh SVK; Leliveld-Kors AM; de Jong IJ; Lub-de Hooge MN; de Vries EGE; Gietema JA; Oosting SF
J Nucl Med; 2017 Jun; 58(6):905-910. PubMed ID: 28082434
[TBL] [Abstract][Full Text] [Related]
13. Correlation of
Zukotynski KA; Vajapeyam S; Fahey FH; Kocak M; Brown D; Ricci KI; Onar-Thomas A; Fouladi M; Poussaint TY
J Nucl Med; 2017 Aug; 58(8):1264-1269. PubMed ID: 28360212
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of vascular endothelial growth factor imaging in human atherosclerotic plaque using (89)Zr-bevacizumab positron emission tomography.
Golestani R; Zeebregts CJ; Terwisscha van Scheltinga AG; Lub-de Hooge MN; van Dam GM; Glaudemans AW; Dierckx RA; Tio RA; Suurmeijer AJ; Boersma HH; Nagengast WB; Slart RH
Mol Imaging; 2013 Jun; 12(4):235-43. PubMed ID: 23651501
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab for the early clinical progression of diffuse intrinsic pontine glioma.
Honda M; Fukuoka K; Tanami Y; Kurihara J; Koh K
Pediatr Int; 2023; 65(1):e15575. PubMed ID: 37551654
[No Abstract] [Full Text] [Related]
16. Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models.
Kossatz S; Carney B; Schweitzer M; Carlucci G; Miloushev VZ; Maachani UB; Rajappa P; Keshari KR; Pisapia D; Weber WA; Souweidane MM; Reiner T
Cancer Res; 2017 Apr; 77(8):2112-2123. PubMed ID: 28108511
[TBL] [Abstract][Full Text] [Related]
17.
Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
[TBL] [Abstract][Full Text] [Related]
18. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
den Hollander MW; Bensch F; Glaudemans AW; Oude Munnink TH; Enting RH; den Dunnen WF; Heesters MA; Kruyt FA; Lub-de Hooge MN; Cees de Groot J; Pearlberg J; Gietema JA; de Vries EG; Walenkamp AM
J Nucl Med; 2015 Sep; 56(9):1310-4. PubMed ID: 26135113
[TBL] [Abstract][Full Text] [Related]
19. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.
Oude Munnink TH; Arjaans ME; Timmer-Bosscha H; Schröder CP; Hesselink JW; Vedelaar SR; Walenkamp AM; Reiss M; Gregory RC; Lub-de Hooge MN; de Vries EG
J Nucl Med; 2011 Dec; 52(12):2001-8. PubMed ID: 22072706
[TBL] [Abstract][Full Text] [Related]
20.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]